Protalix Plans US Resubmission For ERT For Fabry After Positive Phase III Trial Results
You may also be interested in...
Shares in Protalix sank more than 30% after the company received a complete response letter from US regulators for pegunigalsidase alfa for Fabry disease. No inspection of the company's manufacturing plant in Israel appears to be the main sticking point.
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.